Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

T cells, resulting in a delay of distant tumor growth as well. This simple and translatable approach of engineered ECM-binding Abs may present a viable and safer approach in checkpoint blockade.